• Prion-Based Self-Assembly Tunes Mutagenesis

  2026-08-18

  A 2026 Cell study shows that prion-like protein self-assembly can reversibly tune DNA repair and recombination, reshaping mutation supply and adaptive trajectories in yeast. The work connects epigenetic protein states with rapid stress adaptation and drug resistance, including fluconazole resistance in Candida albicans.

• Tetracycline Workflows for Reliable Research

  2026-08-17

  Use Tetracycline as a controlled antibiotic selection marker and a mechanistic probe for bacterial translation, while protecting downstream hepatocyte and HBV assays from avoidable carryover. This workflow links practical reagent handling with the QRICH1–HMGB1 findings reported in hepatic fibrosis research.

• Targeted Peptide Nanocarriers in Breast Cancer Therapy

  2026-08-17

  The 2024 Biomaterials Advances study developed an acid-sensitive, breast-cancer-targeted peptide nanocarrier that co-delivers doxorubicin and triptolide. Its deformable structure improved tumor accumulation and retention while combining direct cytotoxicity with immunogenic cell death and remodeling of the immunosuppressive tumor environment.

• AAPH, Lipid Peroxidation, and Ferroptosis Defense

  2026-08-16

  AAPH offers translational researchers a reproducible way to generate peroxyl-radical stress, model membrane injury, and benchmark antioxidant or repair capacity. When paired with the PRDX6–GPX4 ferroptosis framework, it can help separate nonspecific oxidative damage from pathway-specific lipid-repair mechanisms and improve the design of resistance-aware in vitro studies.

• Targeted Peptide Nanocarriers Enhance Breast Cancer Therapy

  2026-08-15

  The reference study developed DT/Pep1, an acid-sensitive, deformable peptide nanoparticle that co-delivers doxorubicin and triptolide to breast tumors. Its combination of breast cancer targeting, deeper tumor penetration, prolonged intracellular retention, apoptosis induction, and immune activation improved antitumor activity in cellular and 4T1 mouse models.

• ATRX Loss Sensitizes Glioma Cells to RTK Inhibitors

  2026-08-14

  The reference study identifies a genotype-associated vulnerability in high-grade glioma: ATRX-deficient cells show increased sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors. Its combination data with temozolomide support ATRX-stratified interpretation of kinase-inhibitor studies, while also highlighting the need for validation beyond cell-based toxicity assays.

• GGFG Peptide: A Linker-Centered Research Guide

  2026-08-14

  Explore how the Gly-Gly-Phe-Gly (GGFG) peptide functions as a flexible spacer in bioconjugation, peptide engineering, and biomaterial research. This guide connects linker design with peptide–metal-ion assay interpretation while distinguishing established evidence from practical inference.

• JHU-083 Workflow for Glutaminase Research

  2026-08-13

  JHU-083 provides a practical route to probe glutaminase-dependent glutamate biology in cerebral CD11b cells and experimental cerebral malaria models. This workflow combines selective pathway perturbation with glutamate, glutathione, and oxidative-stress measurements to improve mechanistic interpretation.

• Guanabenz Acetate: α2 Signaling Workflow

  2026-08-13

  Build reproducible α2-adrenergic receptor assays with a DMSO-compatible agonist whose subtype profile supports concentration-response and pathway-bias studies. A carefully controlled, hypothesis-generating workflow can also connect receptor pharmacology with GADD34–IRF3 readouts without overstating evidence from antiviral research.

• 3-Aminobenzamide (PARP-IN-1) Workflow Guide

  2026-08-12

  Build reproducible PARP perturbation assays for oxidative stress, endothelial dysfunction, diabetic nephropathy, and host–virus studies. This guide combines practical dosing, controls, readouts, and troubleshooting while separating product-backed findings from workflow recommendations.

• Tetracycline Workflows for Microbiological Research

  2026-08-12

  Use Tetracycline as a tunable antibiotic selection marker, ribosomal perturbation tool, and orthogonal stress probe rather than treating it as a one-size-fits-all reagent. This guide connects practical bacterial workflows with assay-design lessons from a lung adenocarcinoma study while clearly separating established findings from optimization recommendations.

• Relative Viability vs Fractional Killing in Cancer

  2026-08-11

  Hannah R. Schwartz’s dissertation separates drug-induced growth inhibition from actual cell killing, showing that relative viability and fractional viability capture related but non-equivalent biological responses. This distinction provides a practical framework for interpreting in-vitro drug screens, selecting time points, and avoiding overestimation of cytotoxicity when treatment mainly causes proliferative arrest.

• PP 3 as a Causal Control in ROS–Src Assays

  2026-08-11

  Explore how 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine can strengthen PP 2 experiments by separating Src-associated effects from ROS–calcium signaling. This article translates vascular pharmacology findings into a practical control framework for reproducible cell signaling research.

• Lambda Protein Phosphatase for BMAL1 Assays

  2026-08-10

  Lambda Protein Phosphatase (RNase-free) provides a practical dephosphorylation control for antibody validation, phosphorylation site validation, and BMAL1 phase-separation experiments. Its Mn²⁺ dependence and broad activity toward pSer, pThr, pTyr, and pHis make paired treated-versus-untreated assays especially informative.

• Tyrothricin Assays Through a Systems-Biology Lens

  2026-08-08

  Tyrothricin is a peptide antibiotic mixture best understood through both membrane-level biology and time-resolved assay design. This article translates resistance-aware systems thinking into practical antimicrobial research workflows without overstating cross-domain evidence.

754 records 8/51 page Previous Next First page 上5页 678910 下5页 Last page